CervoMed
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an oral p38 alpha inhibitor, for neurodegenerative diseases including dementia with Lewy bodies, frontotemporal dementia, stroke recovery, and ALS. The publicly-traded company is preparing for Phase 3 trials in DLB.
- Company typePublic
- Founded2014
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CervoMed does
CervoMed (NASDAQ: CRVO) is a clinical-stage biotechnology company developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha, which the company identifies as a key driver of synaptic dysfunction in early-stage neurodegenerative disease. The company's lead clinical program targets dementia with Lewy bodies (DLB), the second most common cause of neurodegenerative dementia, with no FDA- or EMA-approved treatments in the US or EU. CervoMed pursues a differentiated patient enrichment strategy using plasma ptau181 levels to identify DLB patients without Alzheimer's co-pathology — a subgroup representing up to 50% of the diagnosed DLB population in which synaptic dysfunction is considered primarily reversible. The lead asset is being developed across four indications: DLB (primary, Phase 3 planned for H2 2026), frontotemporal dementia (Phase 2, FDA Orphan Drug Designation), post-ischemic stroke recovery (Phase 2 Restore trial), and amyotrophic lateral sclerosis (Phase 2 via the UK EXPERTS-ALS platform).
The core technology rests on p38 alpha inhibition, supported by a new stable crystal form of neflamapimod (Phase 1 formulation study) that addressed prior bioavailability issues caused by unstable polymorphs. Clinical evidence includes the Phase 2a AscenD-LB and Phase 2b RewinD-LB trials (43 sites in US, UK, and Netherlands), with reported outcomes of a 3.5% increase in right basal forebrain volume (p=0.022 vs. placebo), 46% functional connectivity increase, and statistically significant improvements on CDR-SB (p<0.001 vs. old capsules; p=0.003 vs. placebo) and CGIC secondary endpoints. A USPTO notice of allowance issued in June 2026 extends composition/method IP protection into 2042, and the company holds FDA Fast Track Designation for DLB plus Orphan Drug Designation for FTD. Leadership includes alumni from Biogen, Vertex, Sanofi, Epizyme, and McKinsey with prior drug launch experience.
CervoMed is pre-revenue with no approved products or commercial distribution. Revenue is contingent on future FDA approval and commercialization of neflamapimod. To date, the company has funded operations through a $149.4M private placement (March 2024, RA Capital-led), a $21.3M NIH/NIA grant for the RewinD-LB trial, and two 2026 financings totaling $20.5M ($10.0M registered direct offering via H.C. Wainwright and a $10.5M private placement with institutional healthcare investors and insiders), with the cash runway extended into Q2 2027. The company is headquartered in Boston, Massachusetts (formerly EIP Pharma Inc., rebranded August 2023 following the merger that consolidated neflamapimod development under the current corporate entity).
CervoMed firmographics
Firmographics- Name
- CervoMed
- Legal name
- CervoMed, Inc.
- Website
- https://cervomed.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CervoMed is a clinical-stage biotechnology company developing neflamapimod, an oral p38 alpha inhibitor, for neurodegenerative diseases including dementia with Lewy bodies, frontotemporal dementia, stroke recovery, and ALS. The publicly-traded company is preparing for Phase 3 trials in DLB.
- Ownership category
- akta.pro rank
CervoMed industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
- akta.pro secondary industries
- Stroke & Vascular Neurology (HLAKAIAG), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)
Keywords
Where CervoMed is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CervoMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Neflamapimod commercialization: Pre-revenue clinical-stage biotechnology company. No approved products. Revenue expected upon FDA approval and commercialization of neflamapimod for dementia with Lewy bodies and potentially other indications including FTD and stroke recovery.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
CervoMed product offering
Product offeringCore offering
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha. The lead candidate is being developed to reverse synaptic dysfunction in dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and post-stroke recovery. The company is pre-revenue with no approved products, advancing through Phase 2b and toward Phase 3 clinical trials.
Product overview
CervoMed is a clinical-stage biotechnology company developing a single lead drug candidate, neflamapimod, an oral small molecule p38 alpha inhibitor being developed for multiple neurodegenerative indications. The product pipeline includes neflamapimod for dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), stroke recovery, and amyotrophic lateral sclerosis (ALS). The company operates clinical programs including the completed Phase 2b RewinD-LB trial and ongoing Phase 2a trials, with plans for Phase 3 in DLB and Phase 2a in FTD and stroke recovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Neflamapimod Investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha to reverse synaptic dysfunction in neurodegenerative diseases. Being developed for DLB, FTD, stroke recovery, and ALS.
- Neflamapimod for Frontotemporal Dementia Development of neflamapimod for frontotemporal dementia, targeting the nonfluent/agrammatic variant primary progressive aphasia patient population.
- Neflamapimod for Stroke Recovery Development of neflamapimod to improve recovery after moderately severe and severe ischemic stroke by enhancing neural plasticity.
Quantifiable outcome
- 3.5% increase in right basal forebrain volume (p=0.022 vs. placebo) at week 16
- +5 more outcomes
Companies that use CervoMed
Customer profileSegments3 records
Ideal customer profiles2 records
CervoMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CervoMed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EXPERTS-ALS Platform (UK)coreNeflamapimod selected for inclusion in the UK's EXPERTS-ALS platform, a randomized multicenter Phase 2 trial designed to rapidly evaluate potential treatments for amyotrophic lateral sclerosis. The trial will evaluate approximately 35 ALS participants over 18-24 weeks, with first patient expected to be dosed by end of 2026. Trial costs are funded by UK government and leading motor neuron disease charities.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
CervoMed competitors and assessment
Company assessmentDirect peers
- Alector: Clinical-stage biotech developing immuno-neurology approaches for FTD, Alzheimer's, and Parkinson's. Directly comparable as a neurodegenerative-focused company with an FTD program targeting a similar patient population as CervoMed's.
- AC Immune: Clinical-stage biotech developing therapeutics for neurodegenerative diseases with active programs in Alzheimer's, Parkinson's, and Down syndrome. Comparable as a CNS-focused company with multiple neurodegenerative programs and similar regulatory designation strategy.
- Cognition Therapeutics: Clinical-stage company focused on neurodegenerative diseases including DLB and Alzheimer's, with small-molecule SASP inhibitors. Highly comparable given the explicit DLB development focus and similar patient-enrichment strategies.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including ALS, FTD, and Parkinson's. Comparable as a CNS-focused company pursuing multiple neurodegenerative indications with a novel mechanism of action.
- Anavex Life Sciences: Clinical-stage biotech developing small molecules for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Rett syndrome. Comparable as a small-cap CNS biotech with a single lead asset targeting synaptic/neuronal dysfunction.
- Prothena: Clinical-stage biotech developing protein-misfolding therapies for neurodegenerative diseases including DLB, Parkinson's, and Alzheimer's. Comparable as a single-asset-focused neuroscience company with active DLB clinical programs.
Broad incumbents
- Lundbeck: Global CNS-focused biopharma with established DLB and movement-disorder portfolio. Comparable as a large incumbent with active DLB commercial interests who could be a natural strategic acquirer or competitor.
- Biogen: Established neurology-focused biopharma with extensive neurodegenerative disease franchise. Relevant given Biogen's active DLB and Alzheimer's programs and because multiple CervoMed executives (CEO, CCO) are Biogen alumni with deep knowledge of competitive dynamics.
- Sage Therapeutics: Approved-product CNS biopharma developing therapies for CNS disorders. Comparable given CNS specialty focus and recent acquisition experience as a small-cap neurology company.
Emerging players
- Passage Bio: Clinical-stage biotech focused on rare CNS disorders including FTD and ALS. Comparable given overlapping FTD indication and clinical-stage status in neurodegenerative disease.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CervoMed social profiles
Digital presenceCervoMed compliance and trust
Trust signalCompliance2 records
CervoMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
CervoMed leadership team
Management profileNumber of profiles
Profiles6 records
CervoMed subsidiaries and ownership
Company hierarchySubsidiaries1 record
CervoMed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CervoMed M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CervoMed
What does CervoMed do?
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha. The lead candidate is being developed to reverse synaptic dysfunction in dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and post-stroke recovery. The company is pre-revenue with no approved products, advancing through Phase 2b and toward Phase 3 clinical trials.
Is CervoMed a public or private company?
CervoMed is a public company. It is classified as public and is currently operating.
When was CervoMed founded?
CervoMed was founded in 2014. It employs 11 to 50 people.
Where is CervoMed based?
CervoMed is headquartered in Boston, United States, in the North America region.
How does CervoMed make money?
One revenue line is on record: neflamapimod commercialization.
Who are CervoMed's main competitors?
Direct peers on record are Alector, AC Immune, Cognition Therapeutics, Denali Therapeutics, Anavex Life Sciences and Prothena. Broad incumbents are Lundbeck, Biogen and Sage Therapeutics. Passage Bio is listed as an emerging player.
Does CervoMed have an API?
No public API is recorded for CervoMed.
What industry is CervoMed in?
CervoMed's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders), with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 541714 and its SIC code is 2834.